Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
All content for Beyond the Endpoint is the property of Duke Clinical Research Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
Reducing hypertension risk isn’t just about cutting salt. This week on Beyond The Endpoint, Emily O’Brien, Manesh Patel, and Jenny Cook talk with Dr. Dhruv Kazi about the complex public health battle against hypertension. From interventions to strategies for patient and physician adherence, this episode covers scalable solutions to change the future of hypertension.
🔗 Access resources related to this episode https://dcri.org/blog/ep-2-bending-curve-rewriting-future-hypertension
Beyond the Endpoint
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
